Hemab Therapeutics (COAG) Financials: Revenue & Earnings
COAG$38.20-0.20 -0.52%
$1.78B
Market Cap
-26.58
P/E
—
Forward P/E
70
Score
Hemab Therapeutics (COAG) Financials: Revenue & Earnings
COAG price $38.20 -0.20 -0.52%
- Ticker
- COAG
- Price
- $38.20
- Change
- -0.20 -0.52%
- Market cap ?
- $1.78B
- P/E ?
- -26.58
- Dividend yield ?
- 0.00%
- Beta ?
- 1.85
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 70
- Value
- 66
- Quality
- 50
- Growth
- 95
Stocklytics score rationale: value 66, quality 50, growth 95.
Financials
| 2025 |
|---|
| 0 |
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for…
Fair value
COAG fair value Not meaningful. Price $38.20.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-10 | — | -0.51 | — | — |
| 2026-08-11 | -0.80 | -0.73 | — | — |
| 2026-05-21 | -23.98 | -23.25 | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-24 | Walbert Keli | Buy | 36.00K | $35.72 | 1.29M |
| 2026-09-24 | Walbert Keli | Other | 0 | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 57. Ownership 120.78%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 7.81M | New | New | 286.81M |
| NOVO HOLDINGS A/S | 4.18M | New | New | 153.55M |
| FMR LLC | 3.70M | New | New | 135.82M |
| CAPITAL INTERNATIONAL INVESTORS | 3.60M | New | New | 132.37M |
| DEEP TRACK CAPITAL, LP | 3.60M | New | New | 132.30M |
| SIREN, L.L.C. | 2.09M | New | New | 76.65M |
| AVORO CAPITAL ADVISORS LLC | 1.93M | New | New | 70.71M |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 1.65M | New | New | 60.60M |
| JPMORGAN CHASE & CO | 1.15M | New | New | 42.33M |
| VANGUARD CAPITAL MANAGEMENT LLC | 780.76K | New | New | 28.68M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 746.04K | New | New | 27.40M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 715.79K | New | New | 26.29M |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 575.43K | New | New | 21.14M |
| BELLEVUE GROUP AG | 550.00K | New | New | 20.20M |
| CITADEL ADVISORS LLC | 523.45K | New | New | 19.23M |
| BLACKROCK, INC. | 283.83K | New | New | 10.43M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 275.00K | New | New | 10.10M |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | 218.29K | New | New | 8.02M |
| GEODE CAPITAL MANAGEMENT, LLC | 211.80K | New | New | 7.78M |
| BRAIDWELL LP | 160.00K | New | New | 5.88M |
| MARSHALL WACE, LLP | 154.67K | New | New | 5.68M |
| WOODLINE PARTNERS LP | 150.04K | New | New | 5.51M |
| AFFINITY ASSET ADVISORS, LLC | 138.03K | New | New | 5.07M |
| ENSIGN PEAK ADVISORS, INC | 115.39K | New | New | 4.24M |
| VANGUARD FIDUCIARY TRUST CO | 112.50K | New | New | 4.13M |
Earnings and financials
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) trades at $38.20, with a market cap of $1.78B and a trailing P/E of -26.58. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2025 |
|---|
| 0 |
Insights · Dividends · Forecast · Financials · Learn